Exec Chat: Myriad CEO Speaks On Defining Its Market And Differentiating Its Offerings
Executive Summary
Myriad CEO Paul Diaz talked to Medtech Insight about how Innovation and investment are two major drivers of differentiation in precision medicine.
You may also be interested in...
Labcorp Buys Myriad Genetics’ Vectra Autoimmune Test Business
Labcorp has agreed to pay $150m in cash for Myriad Genetics’ autoimmune business, one of three major units Myriad is unloading as it tries to narrow its focus to oncology, women's health and mental health diagnostics.
Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential
Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.
Minute Insight: Indigo Diabetes Starts Human Trial Of Subcutaneous Glucose Monitor
The company has enrolled the first patient in the second human trial of its implantable metabolite monitoring system, which it expects could change the game for blood glucose measurement.